Gilteritinib is the first approved second-generation FLT3 inhibitor and is also the first effective FLT3 inhibitor for AML monotherapy (Table 1).108 A randomized open-label phase III trial (ADMIRAL study, NCT02421939) showed that the median OS was significantly longer in the gilteritinib monotherapy group (9.3 months) than in conventional chemotherapy-treated patients (5.6 months) (p < 0.001). Here, FLT3 is linked to acute myeloid leukemia.